In the present study, PD-L1 expression by the primary tumor was higher in patients who were heterozygous/homozygous for the minor alleles of IFN-lambda3 polymorphisms, and their tumors showed resistance to sequential VEGF-targeting therapy. This evidence concerns the gene IFNL3 and neoplasm.